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Letter to the EditorChronic lymphocytic leukaemia (CLL) is the most common blood cancer in the UK, with an incidence of >3500 newly diagnosed cases per year resulting in >1000 deaths. Disease prevalence increases with age, where the majority of patients are >65 years old [1]. CLL is a largely indolent disease and is routinely staged according to the Binet system as follows; stage A (involving 0-2 lymphoid sites), stage B (involving 2-5 lymphoid cites) and stage C (platelets < 1x1011/L or haemoglobin <10g/dL), the 
latter stage reflecting loss of bone marrow function [2]. Whilst for some stage A patients, the disease may remain stable for many decades (median life expectancy of 13 years), for others the disease progresses more rapidly [3]. This observation likely 
reflects the genetic and molecular heterogeneity of CLL. As such there are several prognostic risk factors used to stratify newly diagnosed patients, which include; trisomy-12, 13q/17p/11q23 deletion, advanced stage, males>females, unmutated VH Ig genes, raised lactate dehydrogenase activity and expression of Zap70 and CD38 [4]. CLL is traditionally treated with a combination of chemotherapeutic reagents, namely, Fludarabine/Cyclophosphamide/Rituximab (FCR), however treatment remains challenging within the elderly population [1]. Lately the Brutan’s tyrosine kinase inhibitor, Ibrutinib, has shown great promise for 
the treatment of CLL [5]. However, exceptions are identified as well as treatment resistance prompting further research into CLL treatment strategies [6].Recently upregulation of the cytosolic isoform of branched-chain amino transferase (BCAT1) has been implicated in the disease progression of chronic myeloid leukaemia (CML) [7]. Hattori demonstrated that BCAT1 expression was required for maintenance of CML cells in an undifferentiated state, an important hallmark of cancer [8]. This was achieved through metabolic reprogramming resulting in alterations in cellular 
α-ketoglutarate. Moreover, the authors showed that treating myeloid leukaemia cells with Gabapentin (BCAT1 inhibitor) [9] reduced cell proliferation in colony assays. Taken together, 
these findings suggest that BCAT1 has an important role in CML leukaemogenesis, which offers therapeutic potential for BCAT1 inhibitors, such as gabapentin to form part of new treatment strategies in CML. However, the implications of BCAT1 expression in CLL are currently unknown. Hence we investigated whether BCAT1 was over-expressed in CLL, and if so, was there any evidence to suggest that BCAT1 may be implicated in CLL disease progression.To this end we analysed CLL patient microarray data available from the NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) for the expression of BCAT1 in peripheral blood or bone marrow mononuclear cells at point of diagnosis. The data set analysed herein was GEO accession GSE22762 (GPL570 platform), which consisted of 107 newly diagnosed censored CLL patients. The patient characteristics for this data set as stated in the original study published in [10] had a median age of 63 (33-85) years, of which 66.4% were male, 51.5% were stage A, 24.8% were stage 
B and 23.8% were stage C according to the Binet classification 
system. Initially we stratified the CLL patients according to time 
to first treatment as follows; <100 days (poor), 100–1,000 days (medium) and >1,000 days (good), and searched for the top 250 most dysregulated genes using the GEO2R online analytical tool. Of the 44,754 probes sets available on the GPL570 platform, probe set 226517_at which corresponds to BCAT1 features in the top 100 most dysregulated genes (P=0.0002) according to our 
risk stratification. A complete list of the top 100 genes generated by this analysis is summarised in Supplemental (Table S1). We 
next evaluated whether there was any significant difference in BCAT1 relative expression between our 3 risk groups. The data 
presented in Figure 1 illustrates a significantly higher relative 
BCAT1 expression in patients where time to first treatment was 
<100 days compared with patients where time to first treatment 
was >1,000 days (P<0.001). To corroborate this finding, the data was imported into Gene Spring (Agilent Technologies) for normalisation and background correction using the GC-RMA algorithm. The Gene Spring normalised analysis agreed with the 
relative expression analysis and displayed significantly higher BCAT1 expressing in the <100 days group compared with the >1,000 days group (P<0.001). Since expression of CD38 and Zap70 have major impact on disease progression in CLL, we wanted to 
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verify whether there was an association between CD38/Zap70 expression and BCAT1 using linear regression analysis. The data show no correlation between Zap70 expression and BCAT1 (R2=0.028, P=0.087). However, a very weak positive correlation 
was detected for CD38 and BCAT1 expression (R2=0.167, P<0.001). This suggests that BCAT1 expression is independent to Zap70 and CD38.
Supplemental Table S1: Top 100 dysregulated genes out of 44,754 probe sets from 107 CLL patients stratified according to time to first treatment. Data analysed from NCBI GEO accession GSE22762; GPL570 platform. Data originally published in [10]. Probe set 226517_at corresponding to BCAT1 is highlighted in red.
ID P Value Gene Symbol ID P Value Gene Symbol ID P Value Gene Symbol"209772_s_at" 0.00000039 CD24 "230502_s_at" 0.0000577 no entry "243931_at" 0.000126 no entry"223649_s_at" 6.04E-07 SLC25A39 "210130_s_at" 0.0000615 TM7SF2 "209352_s_at" 0.000126 SIN3B"223696_at" 0.00000118 ARSD "229854_at" 0.0000632 OBSCN "202600_s_at" 0.000131 NRIP1"218903_s_at" 0.00000229 NABP2 "208243_s_at" 0.0000635 CNR1 "221725_at" 0.000132 WASF2"210830_s_at" 0.00000474 PON2 "240493_at" 0.0000654 no entry "208906_at" 0.000133 HNRNPUL 2-BSCL2///BSCL2"243008_at" 0.00000487 RHEB "208779_x_at" 0.0000656 MIR4640///DDR1 "219065_s_at" 0.000138 DPY30///MEMO1"229026_at" 0.00000492 CDC42SE2 "213757_at" 0.0000669 no entry "236940_at" 0.00014 no entry"225280_x_at" 0.00000508 ARSD "229002_at" 0.0000686 FAM69B "210344_at" 0.000143 OSBPL7"223695_s_at" 0.00000592 ARSD "202387_at" 0.0000704 BAG1 "203289_s_at" 0.000145 NPRL3"211475_s_at" 0.00000597 BAG1 "238071_at" 0.0000713 LCN10 "218075_at" 0.000152 AAAS"220172_at" 0.00000707 DCAF17 "239792_at" 0.0000742 UBL7-AS1 "201911_s_at" 0.000154 FARP1"236917_at" 0.00000773 LRRC34 "200999_s_at" 0.0000773 CKAP4 "208748_s_at" 0.000157 FLOT1"33646_g_at" 0.00000773 GM2A "214720_x_at" 0.0000784 SEPT_10 "220068_at" 0.000157 VPREB3"230131_x_at" 0.00000852 ARSD "207793_s_at" 0.0000789 EPB41 "216807_at" 0.00016 CFAP74"205554_s_at" 0.00000864 DNASE1L3 "206181_at" 0.000079 SLAMF1 "227547_at" 0.000166 no entry"223732_at" 0.00000876 SLC23A1 "203796_s_at" 0.0000803 BCL7A "209217_s_at" 0.000167 WDR45"209151_x_at" 0.00000932 TCF3 "48659_at" 0.0000805 MIIP "204454_at" 0.000178 LDOC1"215891_s_at" 0.0000159 GM2A "241520_x_at" 0.0000837 no entry "211630_s_at" 0.000188 GSS"210153_s_at" 0.0000169 ME2 "228588_s_at" 0.0000854 UBE2B "210010_s_at" 0.000189 SLC25A1"226364_at" 0.0000196 HIP1 "227820_at" 0.0000907 TBC1D25 "212563_at" 0.000193 MIR7112"213048_s_at" 0.0000212 SET "230618_s_at" 0.0000948 no entry "200977_s_at" 0.000194 TAX1BP1"235162_at" 0.0000244 MDM4 "220387_s_at" 0.0000968 HHLA3 "223565_at" 0.000198 MZB1"213436_at" 0.0000267 CNR1 "217700_at" 0.000106 CNPY4 "201876_at" 0.000198 PON2
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"204262_s_at" 0.00003 PSEN2 "202599_s_at" 0.000112 NRIP1 "212698_s_at" 0.000199 SEPT_10"225286_at" 0.0000321 ARSD "230967_s_at" 0.000113 USP7 "210304_at" 0.000201 PDE6B"205590_at" 0.0000392 RASGRP1 "238888_at" 0.000115 no entry "226517_at" 0.000206 BCAT1
"234972_at" 0.000041 ARL16 "210401_at" 0.000115 P2RX1 "232792_at" 0.000207 TRIM69
"214182_at" 0.0000455 ARF6 "221286_s_at" 0.000116 MZB1 "225759_x_at" 0.000209 CLMN"219207_at" 0.0000467 EDC3 "203795_s_at" 0.000116 BCL7A "235006_at" 0.000217 CDKN2AI"215749_s_at" 0.0000503 GORASP1 "229699_at" 0.00012 LOC1001 "201644_at" 0.000226 tissue"206413_s_at" 0.000051 TCL1B "214521_at" 0.000121 HES2 "37652_at" 0.00023 CABIN1"202104_s_at" 0.000051 LOC101930112///SPG7 "227299_at" 0.000123 CCNI "224391_s_at" 0.000232 SIAE"210154_at" 0.0000526 ME2 "210364_at" 0.000125 SCN2B "217833_at" 0.000243 SYNCRIP
Figure 1: BCAT1 expression levels stratified according to time to first treatment. Microarray data from GEO accession GSE22762; GPL570 platform 
was stratified according to time to first treatment; <100 days (n=18), 100-1000 days (n=37) and >1000 days (n=40) and analysed for BCAT1 
expression (226517_at probe set). The top 100 most dysregulated genes according to this stratification are summarised in Supplemental Table S1. 
a) Relative BCAT1 expression level at each time point analysed using NCBI GEO2R online tool. 
b) Normalised BCAT1 expression analysed in GeneSpring (Agilent Technologies) with CG-RMA background correction. 
c) Linear regression analysis comparing BCAT1 relative expression with CD38 relative expression (205692_s_at probe set). 
d) Linear regression analysis comparing BCAT1 relative expression with ZAP70 relative expression (214032_at probe set). n=95 for each plot. *P<0.05, ***P<0.001, data analysed by one way-ANOVA with Tukey’s Multiple Comparison Test.
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In adults BCAT1 expression is restricted to the central nervous system, where it has a pivotal role in glutamate metabolism, however the structural homologue, mitochondrial branched-chain amino transferase (BCAT2) is ubiquitously expressed [11]. This suggests a developmental role for BCAT1, and ‘housekeeping’ role for BCAT2. Thus to further investigate BCAT1 expression in CLL, we compared expression levels between haematopoietic stem cells (HSC), CLL patient cells and healthy donor bone marrow (BM) for both BCAT1 and BCAT2 expression. Microarray data sets analysed were obtained from the NCBI GEO and included GEO accession GSE13496 (GPL96 platform) for HSC analysis and GSE4619 (GPL570 platform) for healthy BM analysis. Data sets were imported into Gene Spring for normalisation and CG-RMA correction prior to BCAT1/BCAT2 gene expression analysis. The data presented in (Figure 2) shows that both HSC and CLL cells 
express significantly more BCAT1 compared with BM from healthy 
age matched donors (P<0.01). This finding suggests that BCAT1 expression is lost during normal bone marrow differentiation, and supports the notion presented for CML that BCAT1 expression maintains the leukemic cell a less differentiated state [7]. These 
data are in contrast to BCAT2, where no significant difference in expression was detected between CLL and healthy BM (P>0.05). Furthermore, no correlation between BCAT1 and BCAT2 
expression was detected in CLL (R2=-0.016; P=0.202), suggesting that expression levels are independent. A summary of BCAT1 and BCAT2 normalised expression in CLL linked to our original risk 
stratification is presented in (Table 1). The data presented is the averaged normalised expression for each BCAT probe set and shows that BCAT1 expression (not BCAT2) is linked to disease 
progression, i.e. patients with time to first treatment <100 days 
have significantly higher BCAT1 expression levels.Finally, Kaplan-Meier analysis was performed to evaluate whether BCAT1 expression level could predict CLL patient overall survival 
(OS) and time to first treatment (Figure 3). For this analysis, 
CLL patients were stratified according to normalised BCAT1 expression level; BCAT1(hi) 2.178 to 4.209 (top quartile) and BCAT1(lo) -1.187 to -2.686 (bottom quartile). There were a total of 27 CLL patients in each arm. The data presented in Figure 3 
show that BCAT1(hi) CLL patients have a significantly worse OS compared with BCAT1(lo) (P=0.0015; Hazard Ratio=9.381) and 
a significantly shorter time to first treatment (P=0.0147; Hazard Ratio=3.283). This is in contrast to BCAT2, where no impact was observed when comparing BACT2(hi) with BCAT2(lo) expressers (P>0.05). It must be noted that the data presented here needs 
further risk stratification evaluation and assessment of BCAT1 protein expression at the cellular level.
Figure 2: Comparison of normalised BCAT1 and BCAT2 expression level between CLL cells, haematopoietic stem cells (HSC) and healthy donor bone marrow (BM). 
a) BCAT1 normalised expression level for 107 CLL patients (GEO accession GSE22762; GPL570 platform) was compared with 12 normal HSC samples (GSE13496; GPL96 platform) and 10 healthy BM samples (GSE4619; GPL570 platform). 
b) Respective data comparing normalised BCAT2 expression level. 
c) Linear regression analysis between normalised BCAT1 expression and normalised BCAT2 expression in CLL (R2=-0.016; P=0.202). **P<0.01, ***P<0.001, data analysed by one way-ANOVA with Tukey’s Multiple Comparison Test.
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Table 1: Risk stratification characteristics for BACT expression.
Patient Group 
(prognosis)
Days  to First 
treatment Gene Probe Sets
Mean Normalised 
Expression (log2)*
Good (n=40) >1000 BCAT1 226517_at; 225285_at;  214452_at;  214390_s_at -0.427±1.77BCAT2 215654_at;  203576_at 0.058±0.306
Medium (n=37) 100 to 1000 BCAT1 226517_at; 225285_at;  214452_at;  214390_s_at 0.582±1.75BCAT2 215654_at;  203576_at 0.050±0.382
Poor (n=18) <100 BCAT1 226517_at; 225285_at;  214452_at;  214390_s_at 1.67±1.86BCAT2 215654_at;  203576_at -0.056±0.262
Figure 3: Kaplan-Meier analysis evaluating BCAT1 and BCAT2 expression in CLL. Patients were stratified according to BCAT1(hi); 2.178 to 4.209 (top quartile) and BCAT1(lo); -1.187 to -2.686 (bottom quartile), based on averaged log2 normalised expression values for each BCAT1 probe set (226517_at; 225285_at; 214452_at and 214390_s_at). 
a) Charts show the impact of BCAT1 expression on overall survival and
b) Time to first treatment. 
c) For comparison, the impact of BCAT2 was evaluated. Patients were stratified according to BCAT2(hi); 0.266 to 0.973 (top quartile) and BCAT2(lo); -0.183 to -0.802 (bottom quartile), based on averaged log2 normalised expression values for each BCAT2 probe set (215654_at; 203576_at). Charts show the impact on overall survival and 
d) Time to first treatment. Patients that express intermediate levels of BCAT have been included for comparison: BCAT1(int); -1.132 to 1.790 (interquartile range) and BCAT2 (int); -0.182 to 0.255 (interquartile range) respectively.
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 Taken together, the data presented here using GEO microarray 
data sets demonstrates that BCAT1 is significantly dysregulated 
in CLL. Patients <100 days before first treatment expressed 
significantly higher levels of BCAT1 compared with patients 
>1,000 days before first treatment. We also showed that BCAT1 expression is lost through normal blood cell differentiation, suggesting that BCAT1 may have a functional role in normal haematopoiesis. Finally, disease progression may be predicted 
when CLL patients are stratified according to BCAT1 expression 
level. These findings align with recent studies evaluating the role of BCAT1 in CML and other cancers such as; glioma [12], breast cancer [13], hepatocellular carcinoma [14] and prostate cancer [15]. The clinically approved drug Gabapentin, which can inhibit BCAT1 activity, may therefore have a future role in the treatment 
of these cancers. Furthermore, stratification of patients according to BCAT1 expression level may be important clinically and help predict disease progression in CLL.
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